Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of Sandostatin LAR in diabetic retinopathy
2004-004696-11Phase 3Terminated
- Sponsor
- Novartis
- Start
- May 2005
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of octreotide in diabetic retinopathy (DR), sponsored by Novartis. Primary endpoint: Long-term safety and tolerability of Sandostatin LAR. Started May 2005; status: terminated.
02
Drugs
octreotide
03
Conditions
diabetic retinopathy (DR)
Beyond the preview
Go deeper on 2004-004696-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004696-11.